靶向免疫抑制治疗风湿病患者COVID-19发生率观察
该研究调查了意大利伦巴第2家风湿病中心955例接受靶向合成或生物类DMARD治疗的风湿病患者,通过问卷调查确认COVID-19发生率与同地区普通人群相当(0.62%对0.66%,P=0.92),无重症或需重症监护者,绝大多数患者维持治疗且疾病活动稳定。
要点
- 靶向合成或生物类DMARD治疗者COVID-19确诊率与同地区普通人群无显著差异
- 阳性患者均无严重并发症或需重症监护,且均暂时停用靶向/生物DMARD
- 90.6%患者采取预防措施,93.2%继续治疗,89.5%疾病活动保持稳定
核心结论
- 接受靶向合成或生物类DMARD的风湿病患者COVID-19发生率与严重程度与同地区普通人群无显著差异。
研究设计与样本
- 意大利伦巴第2家风湿病转诊中心2020年2月25日至4月10日随诊的955例风湿病患者参与问卷调查,并与国家统计局伦巴第人群COVID-19发生率比较,病例经鼻咽拭子确诊。
主要发现
- 确诊COVID-19发生率为0.62%,普通人群为0.66%(P=0.92);阳性患者无严重并发症或需重症监护;阳性患者均暂时停用靶向合成或生物类DMARD;90.6%采取预防措施,93.2%继续治疗,89.5%疾病活动稳定。
关键数值与推荐
- 确诊COVID-19发生率0.62%对普通人群0.66%(P=0.92);问卷应答率98.05%;患者平均年龄53.7岁,女性67.4%。
临床怎么用
- 提示风湿病患者在采取预防措施并维持长期靶向/生物DMARD治疗时,COVID-19发生与重症风险未见明显增加,疾病活动多保持稳定。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the incidence and severity of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases treated with targeted synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) compared with that in the general population living in the same Italian region. METHODS: Patients followed up at 2 rheumatology referral centers in Lombardy from February 25, 2020 to April 10, 2020 were invited to participate in a survey designed to identify patients who had confirmed COVID-19, close contact with others with confirmed COVID-19, or symptoms of the infection, and to detect changes in work, behavior, and disease management made in an attempt to prevent infection. The incidence of COVID-19 in the Lombardy population was obtained from the National Institute of Statistics. COVID-19 cases were confirmed by nasopharyngeal swab. RESULTS: The survey was given to 955 patients (531 patients with rheumatoid arthritis, 203 patients with psoriatic arthritis, 181 patients with spondyloarthritis, and 40 patients with connective tissue diseases, vasculitides, or autoinflammatory diseases). These patients had a mean age of 53.7 years, and 67.4% were women. The rate of response to the survey was 98.05%, and the incidence of confirmed COVID-19 cases was consistent with that in the general population (0.62% versus 0.66%; P = 0.92). None of the patients had severe complications or required intensive care treatment, and all of the patients who tested positive for COVID-19 temporarily discontinued ongoing targeted synthetic drug or biologic DMARD therapy. Almost all patients took precautions to prevent the COVID-19 infection (90.6%), and almost all continued treatment with targeted synthetic drugs or biologic DMARDs (93.2%). Disease activity remained stable in 89.5% of patients. CONCLUSION: Our results reflected the attitude of patients with rheumatic diseases regarding the prevention of the infection while maintaining their long-term treatment regimens. The incidence and severity of COVID-19 in patients treated with targeted synthetic drugs or biologic DMARDs was not significantly different from that in the general population in the same region.
引用
- Favalli EG, Monti S, Ingegnoli F, et al. Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data? Arthritis Rheumatol. 2020. PMID: 32506699. doi:10.1002/art.41388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。